Tinkering outside the kinase ATP box: Allosteric (type IV) and bivalent (type V) inhibitors of protein kinases

Kurt J. Cox, Carolyn D. Shomin, Indraneel Ghosh

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Many members of the protein kinase family have emerged as key targets for pharmacological intervention, most notably in cancer. However, the high sequence and structural homology shared by the more than 500 human protein kinases renders it exceedingly difficult to develop selective inhibitors. Most, if not all, existing inhibitors target multiple protein kinases. Current paradigm suggests that an inhibitor that targets multiple kinases and displays polypharmacology is not only acceptable but also often desirable as a therapeutic agent. However, as we move toward personalized medicine the currently acceptable promiscuity is likely to pose significant hurdles in terms of their therapeutic index, especially for diseases that necessitate long-term drug administration. Moreover, selective inhibitors are the only pharmacologically relevant route toward reagents for the dissection of complex signal transduction pathways. This article provides an overview of recent developments in the design of kinase inhibitors that display increasing selectivity by targeting regions outside the highly conserved ATP-binding pocket. These new approaches may pave the way to potentially new avenues for drug discovery while providing valuable tools for studying signal transduction.

Original languageEnglish (US)
Pages (from-to)29-43
Number of pages15
JournalFuture Medicinal Chemistry
Volume3
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Protein Kinase Inhibitors
Protein Kinases
Phosphotransferases
Adenosine Triphosphate
Polypharmacology
Signal Transduction
Precision Medicine
Drug Discovery
Sequence Homology
Dissection
Pharmacology
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Tinkering outside the kinase ATP box : Allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. / Cox, Kurt J.; Shomin, Carolyn D.; Ghosh, Indraneel.

In: Future Medicinal Chemistry, Vol. 3, No. 1, 01.2011, p. 29-43.

Research output: Contribution to journalArticle

@article{8588c4d4d3e94fc79a371835236a9dfa,
title = "Tinkering outside the kinase ATP box: Allosteric (type IV) and bivalent (type V) inhibitors of protein kinases",
abstract = "Many members of the protein kinase family have emerged as key targets for pharmacological intervention, most notably in cancer. However, the high sequence and structural homology shared by the more than 500 human protein kinases renders it exceedingly difficult to develop selective inhibitors. Most, if not all, existing inhibitors target multiple protein kinases. Current paradigm suggests that an inhibitor that targets multiple kinases and displays polypharmacology is not only acceptable but also often desirable as a therapeutic agent. However, as we move toward personalized medicine the currently acceptable promiscuity is likely to pose significant hurdles in terms of their therapeutic index, especially for diseases that necessitate long-term drug administration. Moreover, selective inhibitors are the only pharmacologically relevant route toward reagents for the dissection of complex signal transduction pathways. This article provides an overview of recent developments in the design of kinase inhibitors that display increasing selectivity by targeting regions outside the highly conserved ATP-binding pocket. These new approaches may pave the way to potentially new avenues for drug discovery while providing valuable tools for studying signal transduction.",
author = "Cox, {Kurt J.} and Shomin, {Carolyn D.} and Indraneel Ghosh",
year = "2011",
month = "1",
doi = "10.4155/fmc.10.272",
language = "English (US)",
volume = "3",
pages = "29--43",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "1",

}

TY - JOUR

T1 - Tinkering outside the kinase ATP box

T2 - Allosteric (type IV) and bivalent (type V) inhibitors of protein kinases

AU - Cox, Kurt J.

AU - Shomin, Carolyn D.

AU - Ghosh, Indraneel

PY - 2011/1

Y1 - 2011/1

N2 - Many members of the protein kinase family have emerged as key targets for pharmacological intervention, most notably in cancer. However, the high sequence and structural homology shared by the more than 500 human protein kinases renders it exceedingly difficult to develop selective inhibitors. Most, if not all, existing inhibitors target multiple protein kinases. Current paradigm suggests that an inhibitor that targets multiple kinases and displays polypharmacology is not only acceptable but also often desirable as a therapeutic agent. However, as we move toward personalized medicine the currently acceptable promiscuity is likely to pose significant hurdles in terms of their therapeutic index, especially for diseases that necessitate long-term drug administration. Moreover, selective inhibitors are the only pharmacologically relevant route toward reagents for the dissection of complex signal transduction pathways. This article provides an overview of recent developments in the design of kinase inhibitors that display increasing selectivity by targeting regions outside the highly conserved ATP-binding pocket. These new approaches may pave the way to potentially new avenues for drug discovery while providing valuable tools for studying signal transduction.

AB - Many members of the protein kinase family have emerged as key targets for pharmacological intervention, most notably in cancer. However, the high sequence and structural homology shared by the more than 500 human protein kinases renders it exceedingly difficult to develop selective inhibitors. Most, if not all, existing inhibitors target multiple protein kinases. Current paradigm suggests that an inhibitor that targets multiple kinases and displays polypharmacology is not only acceptable but also often desirable as a therapeutic agent. However, as we move toward personalized medicine the currently acceptable promiscuity is likely to pose significant hurdles in terms of their therapeutic index, especially for diseases that necessitate long-term drug administration. Moreover, selective inhibitors are the only pharmacologically relevant route toward reagents for the dissection of complex signal transduction pathways. This article provides an overview of recent developments in the design of kinase inhibitors that display increasing selectivity by targeting regions outside the highly conserved ATP-binding pocket. These new approaches may pave the way to potentially new avenues for drug discovery while providing valuable tools for studying signal transduction.

UR - http://www.scopus.com/inward/record.url?scp=78650657590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650657590&partnerID=8YFLogxK

U2 - 10.4155/fmc.10.272

DO - 10.4155/fmc.10.272

M3 - Article

C2 - 21428824

AN - SCOPUS:78650657590

VL - 3

SP - 29

EP - 43

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 1

ER -